HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)

Market Cap	233.26B -64.4%
Revenue (ttm)	67.56B +18.1%
Net Income	-9.09B
EPS	-102.96
Shares Out	92.56M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	287,958
Open	2,470.00
Previous Close	2,465.00
Day's Range	2,445.00 - 2,595.00
52-Week Range	2,404.76 - 9,857.14
Beta	-0.72
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About HLB Therapeutics

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 49
• Stock Exchange: KOSDAQ
• Ticker Symbol: 115450

Financial Performance

In 2025, HLB Therapeutics's revenue was 69.56 billion, an increase of 26.63% compared to the previous year's 54.93 billion. Losses were -9.23 billion, -59.52% less than in 2024.